Vipin K. Garg - 25 Jan 2024 Form 4 Insider Report for Altimmune, Inc. (ALT)

Role
President and CEO, Director
Signature
/s/ Richard Eisenstadt, as Attorney-in-Fact
Issuer symbol
ALT
Transactions as of
25 Jan 2024
Net transactions value
$0
Form type
4
Filing time
29 Jan 2024, 18:30:38 UTC
Previous filing
02 Aug 2023
Next filing
01 Feb 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALT Stock Options (option to buy) Award $0 +470,000 $0.000000 470,000 25 Jan 2024 Common Stock, par value $0.0001 470,000 $9.28 Direct F1
transaction ALT Restricted Stock Units Award $0 +168,200 $0.000000 168,200 25 Jan 2024 Common Stock, par value $0.0001 168,200 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent of the shares underlying the option become vested and exercisable on January 25, 2025 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following January 25, 2025, subject to the reporting person's continued service through the applicable vesting date.
F2 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.
F3 The RSUs vest in substantially equal annual installments over the 4 years following January 25, 2024, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.